2015 is going to prove most interesting for Nuvilex, so many milestones have already been achieved with some even bigger milestones just around the corner. EMA Orphan and TGA Orphan pending, both the Phase 1 and Phase 2b clinical trials for pancreatic cancer are scheduled to commence 1Q15 (will run concurrently) and Nuvilex will strive for FDA Accelerated Approval with the Phase 1; with Breakthrough Therapy designation and a Fast Track review from the Phase 1, we could conceivably be looking at FDA approval in the latter part of 2015. This is to mention nothing of the diabetes treatment, which imho is what truly represents the lions share of interest from a big pharma. Don't forget, Dr. Daniel D. Von Hoff has yet to weigh in with the ascites pre-clinicals, which are still being performed, further validating this technology.
Nuvilex has so many coals that are currently in the fire, the possibility of a buyout genuinely exists. Having said that, shorting this stock is a very dangerous proposition. True, big pharmas usually like to wait for revenue - key word being usually - but not always. Small biotechs have been purchased in the past which never produced one cent of revenue. No pumping here, just fact: as recently as June 2014, Merck (MRK) agreed to pay $3.85 billion in cash for biotech Idenix (IDIX), an unprofitable developer of a hepatitis C drug. The deal valued Idenix at ... wait for it ... a nearly 240% premium. You want to short Nuvilex? Go ahead, I couldn't care less. I believe in Nuvilex's world-class technology and their world-renowned scientists. Their competition in the pancreatic cancer and diabetes arena is already a foregone conclusion and big pharma knows this. Some of my previous posts display only a small fraction of the research and due diligence I've performed on Nuvilex. I'm holding long and strong into FDA Accelerated Approval. Merry Christmas to everyone!
News 
Market Data 
Discover 
